GEN Exclusives

More »

The Lists

More »
Jul 22, 2013

Top 25 Biotech Companies of 2013

Which firms made this list this time?

Top 25 Biotech Companies of 2013

These 25 biotech firms are ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares.

  • Last year, GEN published a list of the top 25 biotech companies. So, who would make the list this year? Find out by checking out this updated list of 25 biotech companies ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares.

    Overall, the past year has been mostly very good to biotechs where market cap is concerned, the result of a stock market surge that has not only lifted prices well into double-digits for most of the companies on the list, but also finally jumpstarted the market for initial public offerings after several years of spinning its wheels.

    Indeed, five of the companies saw their market cap more than double, as investors primarily rewarded companies that brought new drugs through trials and FDA review, to market: BioMarin Pharmaceutical, Isis Pharmaceuticals, Onxy Pharmaceuticals, Vertex Pharmaceuticals, and especially Gilead Sciences, which nearly tripled its market cap after spending recent months integrating Pharmasset and growing its strong HIV portfolio with approvals last year for the combination drug Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), as well as and the first drug indicated for preventing the AIDS virus, the combo treatment Truvada (emtricitabine and tenofovir disoproxil fumarate).

    Only two of the top 25 companies on this list (Teva and Elan) saw their share prices decline, in each case following unique challenges that had many of the same biotech investors heading for the proverbial exits.

  • #25. Isis Pharmaceuticals

    2013 Market Cap: $2.324 billion (5/2: 103,780,421 shares * price $22.39)

    2012 Market Cap: $803.473 million (5/3: 100,183,683 shares * price $8.02)

    % Change: 189.2%

    Position on 2012 List: Not ranked

  • #24. Ipsen Group

    2013 Market Cap: $2.889 billion (3/1: 84,100,253 shares * price €26.24)1

    2012 Market Cap: $2.230 billion (3/1: 84,226,573 shares * price €20.26)1

    % Change: 29.6%

    Position on 2012 List: Not ranked

  • #23. United Therapeutics

    2013 Market Cap: $2.966 billion (4/18: 49,707,574 shares * price $59.67)

    2012 Market Cap: $2.260 billion (4/20: 53,685,360 shares * price $42.09)

    % Change: 31.2%

    Position on 2012 List: Not ranked

  • #22. Cubist Pharmaceuticals

    2013 Market Cap: $3.059 billion (4/22: 65,206,393 shares * price $46.91)

    2012 Market Cap: $2.668 billion (4/19: 63,337,315 shares * price $42.13)

    % Change: 14.7%

    Position on 2012 List: Not ranked

  • #21. Ariad Pharmaceuticals

    2013 Market Cap: $3.300 billion (4/30: 184,690,546 shares * price $17.87)

    2012 Market Cap: $2.701 billion (4/30: 165,728,859 shares * price $16.30)

    % Change: 22.2%

    Position on 2012 List: #24

  • #20. Alkermes

    2013 Market Cap: $4.011 billion (5/8: 134,380,999 shares * price $29.85)

    2012 Market Cap: $2.356 billion (5/11: 130,241,192 shares * price $18.09)

    % Change: 70.2%

    Position on 2012 List: Not ranked

  • #19. Seattle Genetics

    2013 Market Cap: $4.390 billion (5/2: 121,265,608 shares * price $36.20)

    2012 Market Cap: $2.316 billion (5/2: 117,051,559 shares * price $19.79)

    % Change: 89.6%

    Position on 2012 List: #25

  • #18. Dr. Reddy’s Laboratories

    2013 Market Cap: $5.014 billion (3/31: 169,836,475 shares * price Rs. 1766.50 on 3/29)1,2

    2012 Market Cap: $5.001 billion (3/31: 169,560,346 shares * price Rs. 1764.75 on 3/30)1,2

    % Change: 0.3%

    Position on 2012 List: #17

  • #17. Onyx Pharmaceuticals

    2013 Market Cap: $6.580 billion (5/3: 72,738,263 shares * price $90.46)

    2012 Market Cap: $3.010 billion (4/27: 64,369,185 shares * price $46.76)

    % Change: 118.6%

    Position on 2012 List: #19

  • #16. Actelion

    2013 Market Cap: $6.885 billion (3/31: 126.7 million shares * price CHF 51.55)1,3

    2012 Market Cap: $4.548 billion (3/31: 130.7 million shares * price CHF 33.00)1,3

    % Change: 51.4%

    Position on 2012 List: #20

  • #15. Elan

    2013 Market Cap: $7.041 billion (3/31: about 596.7 million shares * price $11.80 on 3/28)4,5

    2012 Market Cap: $8.868 billion (3/31: about 590.8 million shares * price $15.01 on 3/30)4,5

    % Change: -20.6%

    Position on 2012 List: #15

  • #14. BioMarin Pharmaceutical

    2013 Market Cap: $9.097 billion (4/19: 139,010,175 shares * price $65.44)

    2012 Market Cap: $3.788 billion (4/13: 115,700,983 shares * price $32.74)

    % Change: 140.2%

    Position on 2012 List: #16


Readers' Comments

Posted 07/28/2013 by James Thornton

It would be helpful if you also were to list the main product line or service provided by these companies.
Jim Thornton

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?